Ultra-low dose - new approaches in menopausal hormone therapy.

Details

Serval ID
serval:BIB_664B592993F7
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Ultra-low dose - new approaches in menopausal hormone therapy.
Journal
Climacteric
Author(s)
Stute P., Becker H.G., Bitzer J., Chatsiproios D., Luzuy F., von Wolff M., Wunder D., Birkhäuser M.
ISSN
1473-0804 (Electronic)
ISSN-L
1369-7137
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
18
Number
2
Pages
182-186
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
Despite increasing life expectancy, the age of onset of natural menopause has not significantly changed in recent decades. Thus, women spend about one-third of their lives in an estrogen-deficient state if untreated. There is a need for appropriate treatment of acute symptoms and prevention of the sequelae of chronic estrogen deficiency. International guidelines call for the use of the lowest effective hormone dosage for vasomotor symptom relief, the major indication for menopausal hormone therapy (MHT). In 2011, an oral continuous combined ultra-low-dose MHT was approved in Switzerland. This publication was elaborated by eight national menopause specialists and intends to review the advantages and disadvantages of ultra-low-dose MHT after the first years of its general use in Switzerland. It concludes that, for many women, ultra-low-dose MHT may be sufficient to decrease vasomotor symptoms, but not necessarily to guarantee fracture prevention.
Pubmed
Web of science
Create date
18/04/2015 12:27
Last modification date
20/08/2019 14:22
Usage data